Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 1839100 in Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis With Clinically Meaningful Cough
NCT06360094Phase 2Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2024
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 24
01
Overview
A Phase 2 trial of BI 1839100 in idiopathic pulmonary fibrosis (IPF), pulmonary fibrosis (PF), sponsored by Boehringer Ingelheim. Started Aug 2024; status: terminated.
02
Drugs
BI 1839100
03
Conditions
idiopathic pulmonary fibrosis (IPF)pulmonary fibrosis (PF)
Beyond the preview
Go deeper on NCT06360094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06360094.